Abstract Number: PB0241
Meeting: ISTH 2021 Congress
Background: The concept of immunothrombosis has established as a central pathogenic factor leading to thrombosis complications, respiratory failure, and a multiple organ failure in patents with COVID-19. Studying of the hypercoagulability in patients with COVID-19 could be useful for improving of disease’s outcomes. Estimation of anticoagulants efficiency can be informative for thrombotic risk assessment. The highest interest presents protein C system, because, as we know, infection and inflammation lead to disfunction of this anticoagulant system.
Aims: To estimate the efficiency of protein C anticoagulant system in COVID-19 patients.
Methods: The study included 60 patients with COVID-19 and 21 healthy controls . Thrombin generation was assessed by CAT according to Hemker et al. Measure was conducted in platelet poor plasma with or without presence of thrombomodulin. The following parameters were determined: endogenous thrombin potential (ETP, nM*min), peak thrombin (Peak, nM). Sensitivity ETP and Peak for thrombomodulin were calculated as percent of decreasing of these parameters after adding thrombomodulin to the assay. Reduction of sensitivity for thrombomodulin indicates dysfunction of anticoagulant protein C system. Protein C activity and free protein S level were measured by “ACL ELIT PRO”, Instrumentation Laboratory, USA. STATISTICA 12.0 package was used. Results are presented as median with 95% confidence intervals, p<0.05 was considered statistically significant (*).
|Parameters||Patients (n=60)||Controls (n=21)|
|Sensitivity ETP (%)||11,0 (0,0-61,3) *||51,5 (22,5-65,5)|
|Sensitivity Peak (%)||4,0 (0,0-39,0) *||35,5(14,6-53,8)|
|Protein C activity (%)||99,0 (62,5-132,6)||102,0 (76,6-145,0)|
|Free protein S level (%)||64,2 (34,1-106,5) *||79,0 (58,3-112,0)|
Sensitivity ETP and Peak for thrombomodulin, protein C activity and free protein S level are presented in the table.
Sensitivity ETP and Peak for thrombomodulin were vastly lower in patients with COVID-19. Free protein S level was significantly reduced in patient’s group, protein C activity did not differ in the groups.
Conclusions: The efficiency of protein C anticoagulant system is depressed in COVID-19 patients. It may be associate with protein S level decreasing. The disability of anticoagulant protein C system can lead to hypercoagulability and it may be cause of thrombotic complication.
To cite this abstract in AMA style:Matvienko O, Korsakova N, Lerner A, Shvedova T, Papayan L, Golovina O. Efficiency of Anticoagulant Protein C System in Patients with Coronavirus Infection Caused by the SARS-CoV-2 [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/efficiency-of-anticoagulant-protein-c-system-in-patients-with-coronavirus-infection-caused-by-the-sars-cov-2/. Accessed November 29, 2023.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/efficiency-of-anticoagulant-protein-c-system-in-patients-with-coronavirus-infection-caused-by-the-sars-cov-2/